The OK for mResvia adds another option for preventing RSV-related disease in older adults, one year after the agency cleared shots from GSK and Pfizer.
Moderna has secured FDA approval for its respiratory syncytial virus (RSV) vaccine, giving it a chance to generate revenue from a second product as sales of its Spikevax COVID-19 shot have slumped.
Synopsys VC Verification IP (VIP) for ARM® AMBA® AXI™ provides complete protocol support for AXI3™, AXI4™, AXI4-Lite™, AXI4-Stream™, ACE™, ACE-Lite™ , AHB™ and APB™ interfaces. ... Synopsys® VC ...
Moderna’s shot is the third RSV vaccine for people 60 and older that’s gotten the green light from the FDA and the first mRNA vaccine among them. It’s the company’s second product to ...
The U.S. Food and Drug Administration has approved Moderna's respiratory syncytial virus vaccine, the company announced on Friday, giving it a shot at much-needed new revenue from a second product.
The US Food and Drug Administration approved Moderna’s respiratory syncytial virus (RSV) vaccine, the company announced on Friday, giving it a shot at much-needed new revenue from a second product.
Moderna Inc. has landed its second product approval from the U.S. Food and Drug Administration after its COVID-19 vaccine. The Cambridge drugmaker’s mRNA vaccine for respiratory syncytial virus ...
Moderna Chief Executive Officer Stéphane Bancel talks about how the biotech giant is cutting costs and developing new vaccines. The drugmaker expects to have its vaccine for respiratory syncytial ...
CAMBRIDGE, MA - Moderna , Inc. (NASDAQ:MRNA) has received approval from the U.S. Food and Drug Administration (FDA) for its mRNA respiratory syncytial virus (RSV) vaccine, mRESVIA, to prevent lower ...